66 related articles for article (PubMed ID: 11366114)
21. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
22. Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.
O'Meara JA; Yoakim C; Bonneau PR; Bös M; Cordingley MG; Déziel R; Doyon L; Duan J; Garneau M; Guse I; Landry S; Malenfant E; Naud J; Ogilvie WW; Thavonekham B; Simoneau B
J Med Chem; 2005 Aug; 48(17):5580-8. PubMed ID: 16107158
[TBL] [Abstract][Full Text] [Related]
23. High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.
Cancio R; Silvestri R; Ragno R; Artico M; De Martino G; La Regina G; Crespan E; Zanoli S; Hübscher U; Spadari S; Maga G
Antimicrob Agents Chemother; 2005 Nov; 49(11):4546-54. PubMed ID: 16251294
[TBL] [Abstract][Full Text] [Related]
24. New drugs for old.
Winston A; Stebbing J
J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
[TBL] [Abstract][Full Text] [Related]
25. Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones.
He Y; Chen F; Yu X; Wang Y; De Clercq E; Balzarini J; Pannecouque C
Bioorg Chem; 2004 Dec; 32(6):536-48. PubMed ID: 15530994
[TBL] [Abstract][Full Text] [Related]
26. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
Liu J; Yue J; Wu S; Yan Y
Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
[TBL] [Abstract][Full Text] [Related]
27. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
Domaoal RA; Demeter LM
Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
[TBL] [Abstract][Full Text] [Related]
28. An introduction to nucleoside and nucleotide analogues.
Squires KE
Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
[TBL] [Abstract][Full Text] [Related]
29. New antiretroviral agents.
Gallant JE
Hopkins HIV Rep; 1999 Mar; 11(2):3, 12. PubMed ID: 11366248
[TBL] [Abstract][Full Text] [Related]
30. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
[TBL] [Abstract][Full Text] [Related]
31. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
[TBL] [Abstract][Full Text] [Related]
32. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
[TBL] [Abstract][Full Text] [Related]
33. Investigational reverse transcriptase inhibitors for the treatment of HIV.
Cory TJ; Midde NM; Rao P; Kumar S
Expert Opin Investig Drugs; 2015; 24(9):1219-28. PubMed ID: 26088266
[TBL] [Abstract][Full Text] [Related]
34. Invirase and cross resistance.
AIDS Patient Care; 1995 Oct; 9(5):256. PubMed ID: 11361409
[No Abstract] [Full Text] [Related]
35. Advocates call for fair drug pricing.
Highleyman L
BETA; 1998 Oct; ():3. PubMed ID: 11365988
[TBL] [Abstract][Full Text] [Related]
36. Different HIV-1 strains found in semen and blood.
Birchard K
Lancet; 1998 Oct; 352(9137):1363. PubMed ID: 9802285
[No Abstract] [Full Text] [Related]
37. Promising results for SPV-30.
AIDS Patient Care; 1995 Oct; 9(5):259. PubMed ID: 11361421
[No Abstract] [Full Text] [Related]
38. Will NNRTIs be driving forward again?
Calmy A; Tarr PE
Lancet HIV; 2018 May; 5(5):e200-e201. PubMed ID: 29592841
[No Abstract] [Full Text] [Related]
39. New nonnucleoside reverse transcriptase inhibitors.
GMHC Treat Issues; 1999 Feb; 13(2):10. PubMed ID: 11366114
[TBL] [Abstract][Full Text] [Related]
40. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection?
Kilby JM; Saag MS
Infect Agents Dis; 1994 Dec; 3(6):313-23. PubMed ID: 7534192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
